INTRODUCTION {#SEC1}
============

During HIV-1 reverse transcription, the reverse transcriptase (RT) transcribes (+) strand viral RNA genome to form integration-competent double stranded DNA ([@B1]). RT is a p66/p51 heterodimer that exhibits RNA- and DNA-directed DNA polymerase and RNAse H activities. The p66 subunit is enzymatically active and can be structurally divided into thumb, palm, fingers and connection sub-domains and RNase H domain ([@B2],[@B3]). Although the p51 subunit shares the same polypeptide chain as the p66 subunit with the exception of the last 120 C-terminal amino acids, its role seems to be purely structural ([@B2]--[@B4]). Because of its critical role in reverse transcription and thus in retroviral replication, RT is an important target for anti-HIV drugs and two well represented classes of approved RT-inhibitor drugs are available ([@B5]--[@B7]). The first class called nucleoside reverse transcriptase inhibitors (NRTI) consists of nucleotide analogues such as Zidovudine (AZT), which directly compete with dNTP monomers to block the extension of the primer. The second class called non-nucleoside reverse transcriptase inhibitors (NNRTI) is composed of molecules structurally unrelated to nucleotides that bind non-competitively to RT allosteric sites ([@B8],[@B9]). Both of these inhibitor classes, substantially slow down the progression of the virus. However, even when the two classes are used in association, the high prevalence of mutations in the HIV-1 genome results in the selection of drug resistant strains, leading to frequent viral escapes over the long term patient\'s therapeutic management. In this context, a continuous development of new RT inhibitor drugs targeting the enzymatic activities of RT is needed ([@B10]--[@B12]). Alternatively, since RT is regulated by a number of other HIV-1 proteins in the reverse transcription complex (RTC), these proteins may constitute additional targets to block the reverse transcription process. For instance, an attractive complementary target could be the HIV-1 nucleocapsid protein NCp7 ([@B13]--[@B15]), a highly conserved 55-amino acid protein, characterized by two zinc finger motifs, that is quantitatively the main HIV-1 protein in RTC. NCp7 is thought to promote reverse transcription through its nucleic acid chaperone activity ([@B16]--[@B21]), but also by stabilizing the complex of RT with its substrate ([@B22]--[@B24]) and/or through direct interaction with RT ([@B25]--[@B27]).

Multiple assays have been reported to investigate and monitor RT polymerization activity. Most of these assays are usually discontinuous multistep assays, using radioactively or fluorescently labeled nucleotide analogs ([@B28]--[@B42]) and requiring extensive sample handling. Recently, a number of fluorescence-based approaches have been developed to further characterize the kinetics and mechanism of RT ([@B43]--[@B47]). Based on these approaches, RT was notably shown to dynamically flip between two opposite orientations on its substrate, namely a polymerase conformation, where the finger sub-domain is toward the primer 3′ end and a RNase H conformation, where the RNase H domain is toward the primer 3′ end, explaining how the binding mode of RT tunes its enzymatic activity ([@B43],[@B46]). Based on these data, we recently developed a one-step and one-pot assay using Förster resonance energy transfer (FRET) between fluorescently labeled RT and primer/template (p/t) that allows monitoring RT flipping and polymerization in real time ([@B48]). This assay was shown to discriminate non-nucleoside RT inhibitors from nucleoside RT inhibitors and to determine reliably their potency. Though this assay is highly sensitive and convenient, it suffers from the need to produce a RT mutant with a single accessible Cys, to label it by a fluorophore and to purify it, in an enzymatically active state. Therefore, this assay can hardly be used with wild-type RT or with RT mutants resistant to RT inhibitors. In order to overcome these limitations, we proposed here a continuous one-pot FRET-based polymerization assay, using a commercially available doubly-labeled p/t similar to that previously used in single molecule experiments for monitoring RT polymerase activity ([@B46]). Through this assay, the RT-mediated extension of the primer as well its promotion by NCp7 could be monitored in real time, by conventional fluorescence techniques. Therefore, we propose here a simple and robust assay for screening and validating anti-RT and anti-NCp7 molecules.

MATERIALS AND METHODS {#SEC2}
=====================

Proteins {#SEC2-1}
--------

Recombinant, heterodimeric mutant of HIV-1~BH10~ RT was expressed in Escherichia coli and purified as described previously ([@B49]). The expression system and purification protocol allowed the preparation of large quantities of heterodimeric enzyme in a homogeneous form. The prepared RT contains a E478Q mutation in its RNase H domain, but it was previously checked that this mutation does not affect the polymerase activity ([@B50]). RT labeled in its p51 thumb subdomain by Alexa 488 was prepared and its activity was tested as described ([@B48]). Proteins were stored at −80°C. Protein concentrations were determined using extinction coefficients at 280 nm of 260 450 M^−1^ cm^−1^.

Full length NCp7 peptide was synthesized by solid-phase peptide synthesis on a 433A synthesizer (ABI, Foster City, CA, USA) as described ([@B51]). Purification by HPLC was carried out on a C8 column (Uptisphere 300 A, 5 μm; 250 × 10, Interchim, France) in 0.05% trifluoroacetic acid (TFA) with a linear gradient of 10--70% of acetonitrile for 30 min. The peptide purity and molecular weight were checked by LC/MS. An absorption coefficient of 5700 M^−1^ cm^−1^ at 280 nm was used to determine its concentration.

Nucleotides, RT-inhibitors {#SEC2-2}
--------------------------

The deoxynucleotide (dNTP) mixture was prepared by mixing each of UltraPure dATP, dCTP, dGTP and dTTP, purchased from Sigma Aldrich. Nevirapine (*11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido\[3,2-b:2′,3′-e\]\[1,4\]diazepin-6-one*) was also purchased from Sigma Aldrich and its stock solution was dissolved in dimethyl sulfoxide (DMSO). AZT triphosphate (3′-Azido-3′-Deoxythymidine-5′ Triphosphate) was purchased from Genexxon bioscience (Germany).

Oligonucleotides {#SEC2-3}
----------------

Synthetic purified oligodeoxynucleotides were purchased from IBA (Göttingen, Germany) with the necessary modifications and their concentrations were determined by UV absorbance at 260 nm by using the extinction coefficients provided by the supplier. FRET measurements were carried out using a 23-mer (5′- CAG CAG TAC AAA TGG CAG TAT TC) DNA-primer labeled at the T19 position with Cyanine 5 (Cy5), annealed to a 63-mer (3′-TGT CGT CAT GTT TAC CGT CAT AAG TAG GTG TTA CTA GTC CGA TTT CCC CTA GTC CGA CCC ATG)-template labeled at the T2 position with carboxytetramethylrhodamine (TMR). Both TMR and Cy5 were covalently attached by supplier, via a C6 amino link to their respective T residues in the primer and the template. Primer and template oligodeoxynucleotides were annealed by heating equimolar amounts in buffer at 90°C for 2 min, followed by cooling to room temperature over several hours in a heating block. Unless noted otherwise, all experiments were routinely carried out at 20°C in a buffer containing 50 mM Tris--HCl (pH 7.5), 10 mM KCl and 6 mM MgCl~2~.

Fluorescence measurements {#SEC2-4}
-------------------------

All steady-state and kinetic experiments were performed using the doubly-labeled p/t duplexes, which are mentioned above, in the presence of HIV-1 RT. All measurements were performed at 20°C using either a Fluoromax 4 spectrofluorometer (Jobin-Yvon Horiba) or a stopped-flow apparatus (SF3, Biologics). The FRET donor, TMR, was excited at 540 nm, and its emission was recorded at 580 nm. Nucleotide incorporation kinetics was triggered by addition of deoxyribonucleotides (dNTPs) in excess to a pre-incubated mixture of HIV-RT and p/t duplexes at equimolar concentrations. The kinetics was fast enough to monitor the fluorescence intensities continuously without photobleaching. The annealing kinetic traces were adequately fitted using: $$\documentclass[12pt]{minimal}
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}{}\begin{equation*} I(t) = I_F - (I_F - I_0 )(ae{}^{ - k_{{\rm obs1}} (t - t0)} - (1 - a)e{}^{ - k_{{\rm obs2}} (t - t0)}) \end{equation*}\end{document}$$ where *t~0~* is the dead time, *k*~obs1,2~ are the observed kinetic rate constants, *a* is the amplitude of the fast component, and *I~0~* and *I~F~* are the fluorescence intensities before dNTPs addition and at completion of the reaction, respectively. The *I*~0~ value was obtained from the steady-state fluorescence spectrum of the doubly labeled p/t duplex in the presence of RT and was thus fixed. All fitting procedures were carried out with Origin™ 8.6 software using nonlinear, least-square methods and the Levenberg-Marquardt algorithm. Analytical analysis was systematically cross-validated using Bayesian inference with Markov Chain Monte Carlo and Gibbs sampling (see Supplementary Data and Supplementary Figures S1 and 2).

Measurements in high-throughput screening (HTS) format {#SEC2-5}
------------------------------------------------------

Experiments were performed in 96-well plates. The complex of RT with p/t was formed by mixing 100 nM RT and 100 nM doubly-labeled p/t duplex in a total volume of 200 μl. All measurements were performed at 20°C using a FLX-Xenius plate reader (Safas Monaco). Excitation wavelength was 540 nm and emission was recorded at 580 nm using 10 nm slits. Polymerization kinetics were triggered by addition of 100 μM dNTPs. When kinetics were recorded in the presence of RT-inhibitors, the RT--p/t complex was pre-incubated with inhibitors for at least 5 min, unless otherwise stated. Each set of experiments was performed in three independent triplicates.

RESULTS AND DISCUSSION {#SEC3}
======================

Design and validation of the assay {#SEC3-1}
----------------------------------

A HIV-1 relevant DNA/DNA p/t sequence was selected from the HIV-1 *pol* gene. This p/t sequence lies outside any reported pausing-site ([@B52]) and thus, can be used to mimic a naturally occurring polymerization step during the plus strand synthesis of the HIV-1 genome. The doubly labeled p/t duplex was prepared by heat-annealing a 63-nt long DNA template labeled close to its 5′ end at its T2 position by TMR, used as a FRET donor, with a 23-nucleotide long DNA primer labeled at its T19 position with Cy5, used as a FRET acceptor (Figure [1A](#F1){ref-type="fig"}). The TMR label was placed 38 nt away from the 3′ end of the primer and 42 nt away from the Cy5 label and thus should not perturb RT binding.

![Design and validation of the FRET based assay. (**A**) Schematic representation of the FRET-based assay. The DNA--DNA p/t was labeled with both TMR (green) and Cy5 (red). Addition of RT and dNTP led to extension of the DNA primer, which shifted the two dyes further apart from each other, resulting in a decrease in FRET. (**B**) Polymerization kinetic trace of 100 nM RT with 100 nM doubly-labeled p/t duplex on addition of 100 μM dNTPs (red trace). The black line corresponds to the fit of the trace by Equation ([1](#M1){ref-type="disp-formula"}), with *k*~obs1~ = 19 (±1) × 10^−3^ s^−1^, *k*~obs2~ = 17 (±3) × 10^−4^ s^−1^ and *a* = 0.35 (±0.1). (Inset) Emission spectra of the doubly-labeled duplex in the absence (black line) and the presence (red line) of RT and after completion of polymerization with the addition of 100 μM dNTPs (blue line). For comparison, the emission spectrum of the duplex with TMR-labeled template and non-labeled primer (pink line) in the presence of RT is given to indicate the emission of the donor alone. Excitation and emission wavelengths for the kinetic trace were 540 and 580 nm, respectively.](gkv1532fig1){#F1}

Heat-annealed duplexes of labeled primer and template resulted in an FRET efficiency of 65% (Figure [1B](#F1){ref-type="fig"}, inset). This high value indicates that the average inter-dye distance is very short (∼ 4.5 nm), suggesting that the single-stranded domain of the template is highly flexible, bringing the 5′ end of the template close to the 3′ end of the unextended primer (Figure [1A](#F1){ref-type="fig"}). Formation of the complex between RT and DNA p/t (hereinafter referred to as E.DNA) led to a marginal decrease in FRET (from 65 to 63%), indicating that RT binding induces marginal changes in the distance between the two chromophores. In contrast, addition of 100 μM dNTPs led to a progressive increase in TMR fluorescence that reached a plateau, corresponding to 16% FRET, in about 45 min (Figure [1B](#F1){ref-type="fig"}), due to the increase in the distance (from ∼4.5 to ∼7 nm) between the fluorescent dyes as the full ds-duplex forms. As a control, neither the binding of RT nor the extension of the duplex was found to significantly affect the fluorescence of the same duplex labeled only with TMR (Supplementary Figure S3), clearly indicating that the FRET changes observed in Figure [1](#F1){ref-type="fig"} were reflecting the polymerization activity of RT.

The progress curve in Figure [1B](#F1){ref-type="fig"} could be adequately fitted by a biexponential equation (Equation [1](#M1){ref-type="disp-formula"}) with *k*~obs1~ = 19 (±1) × 10^−3^ s^−1^ and *k*~obs2~ = 17 (±3) × 10^−4^ s^−1^. Surprisingly, these rate constants were at least 10-fold slower as compared to the dNTP incorporation rates (0.1--0.4 s^−1^) reported under similar experimental conditions ([@B43],[@B53]--[@B55]). To check whether these slower rate constants may be related to the Cy5 label in the primer sequence (Figure [2A](#F2){ref-type="fig"}), we monitored the polymerization reaction by using RT labeled in its p51 thumb subdomain by Alexa 488 and a duplex where the Cy5-labeled primer is annealed to the template labeled at its 3′ end by TMR (Figure [2B](#F2){ref-type="fig"}). In this approach, the polymerization is monitored through the changes in FRET between the Alexa 488-labeled RT and the TMR label in the p/t. In line with previous data where a similar approach has been used with a non labeled primer ([@B48]), the obtained *k*~obs~ values (*k*~obs1~ = 17 (±3) × 10^−2^ s^−1^, *k*~obs2~ = 9 (±2) × 10^−3^ s^−1^) were similar to the dNTP incorporation rates ([@B46],[@B48],[@B53]), indicating that the Cy5 label in the primer does marginally affect RT polymerization. An alternative hypothesis may be that the TMR-containing region in the template is progressively folded during primer extension (Figure [1A](#F1){ref-type="fig"}), giving complex changes in the distance and thus, in the FRET efficiency between TMR and Cy5, so that the observed fluorescence signal is no more directly related to the number of nucleotides incorporated. To check this hypothesis, we compared the elongation kinetic traces of E.DNA with those obtained with E.DNA + 9 and E.DNA + 21 primers (Figure [2A](#F2){ref-type="fig"}) that were extended by respectively 9 and 21 nt, in respect with E.DNA (Figure [2C](#F2){ref-type="fig"}). Interestingly, though the primer was only extended by 9 nt in E.DNA + 9, the initial donor fluorescence was already close that of the final plateau, which as expected, strongly affected the amplitude associated to *k*~obs1~ (from 0.35 to 0.85). Moreover, the initial fluorescence of the trace with E.DNA + 21 was even higher than the plateau, indicating that the distance between the two dyes was increased as compared to the fully extended ds-DNA duplex. This increased distance likely results from the about 2-fold increased length per base of single stranded DNA as compared to double stranded DNA ([@B56]), so that at least for short segments, higher inter-chromophore distances can be achieved. Both the E.DNA + 9 and E.DNA + 21 data clearly indicate that the fluorescence changes observed as RT elongates the p/t DNA results from complex donor--acceptor distance changes, so that the apparent rate constants retrieved from the experimental curves do not reflect the real catalytic rates of RT.

![Kinetic curves with primers of different lengths. (**A**) Nucleic acid substrate sequences used in this study. Acceptor and donor fluorophores are attached by a linker to the T residues represented in red and green, in the primer and template sequences, respectively. (**B**) Polymerization kinetic trace of 100 nM RT labeled in its p51 thumb subdomain by Alexa 488 with 100 nM duplex, where the Cy5-labeled primer is annealed to the template labeled at its 3′ end by TMR, upon addition of 100 μM dNTPs. The black line corresponds to the fit of the trace by Equation ([1](#M1){ref-type="disp-formula"}), with *k*~obs1~ = 17 (±3) × 10^−2^ s^−1^, *k*~obs2~ = 9 (±2) × 10^−3^ s^−1^ and *a* = 0.5 (±0.1). Excitation and emission wavelengths were 480 and 520 nm, respectively. (**C**) Polymerization kinetic trace of 100 nM E.DNA (gray), 100 nM E.DNA + 9 (red) and E.DNA + 21 (blue) in the presence of 100 μM dNTP. All traces were fitted by Equation ([1](#M1){ref-type="disp-formula"}). Fitting of the gray trace according to Equation ([1](#M1){ref-type="disp-formula"}) provides *k*~obs1~ = 19 (±1) × 10^−3^ s^−1^, *k*~obs2~ = 17 (±3) × 10^−4^ s^−1^ and *a* = 0.35 (±0.1), fitting of the red trace provides *k*~obs1~ = 14 (±1) × 10^−3^ s^−1^, *k*~obs2~ = 13 (±3) × 10^−4^ s^−1^ and *a* = 0.85 (±0.1) and fitting of the blue trace provides *k*~obs1~ = 18 (±2) × 10^−2^ s^−1^, *k*~obs2~ = 63 (±5) × 10^−4^ s^−1^ and *a* = 0.5 (±0.1). Excitation and emission wavelengths were 540 and 580 nm for the kinetic traces, respectively.](gkv1532fig2){#F2}

Next, we explored the dependence of the *k*~obs~ values on the dNTP concentrations to further identify the mechanistic steps monitored by this assay (Supplementary Figure S4). From the analysis of this dependence, the assay is thought to monitor the formation of the final extended duplex via two parallel pathways that depend on the initial binding events of RT to the p/t substrate. In this proposed mechanism, the lower pathway corresponds to the primer extension by RT properly bound in polymerase orientation, while the upper and slower pathway is related to either RT flipping or dissociation-rebinding of RT faulty bound on the nucleic acid substrate (Supplementary Figure S4).

Use of the assay to monitor the effect of RT inhibitors {#SEC3-2}
-------------------------------------------------------

As the assay monitors the RT polymerization, we next evaluated its ability to screen for RT inhibitors. To this end, we monitored the effect of two well-characterized RT inhibitors, Nevirapine and Zidovudine (AZTTP) ([@B5]--[@B7],[@B57]), on the FRET-based kinetic curves. Inhibitors were serially diluted and pre-incubated at increasing concentrations with the E.DNA complex in cuvettes as well as in 96-well plates. The polymerization reaction was then triggered by adding dNTPs. In the presence of AZTTP, we observed a dramatic dose-dependent decrease of the values of the fluorescence intensity plateau (Figure [3A](#F3){ref-type="fig"}) and the two kinetic rate constants (Figure [3B](#F3){ref-type="fig"}). The changes in *k*~obs1~ and *k*~obs2~ values (Figure [3B](#F3){ref-type="fig"}) as a function of the inhibitor concentrations, *I*, were then used to determine *IC*~50~ values, according to ([@B58]): $$\documentclass[12pt]{minimal}
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}{}\begin{equation*} k_{{\rm obs1},{\rm 2}} = \frac{{k_{{\rm obs}0} + \left( {k_{{\rm obsf}} - k_{obs0} } \right)}}{{1 + 10^{\left( {\log (IC_{50} ) - \log (I))*p} \right)} }} \end{equation*}\end{document}$$ where *k*~obs0~ and *k*~obsf~ represent the *k*~obs~ values in the absence and at saturating concentration of inhibitor, respectively. *IC*~50~ represents the half maximal inhibitory concentration and *p* denotes the Hill coefficient. *IC*~50~ values determined for AZTTP were found to be 7 (±1) μM and 6 (±1) μM for *k*~obs1~ and *k*~obs2~, respectively. These values are in good agreement with the values reported in literature ([@B48],[@B59]).

![RT polymerization in the presence of RT inhibitors. (**A**) Representative set of kinetic traces of 100 nM E.DNA in the absence (gray) or in the presence of increasing concentrations of AZTTP (red---1 μM, blue---3 μM, magenta---5 μM, dark green---10 μM, cyan---20 μM) recorded in a 96-well plate. The black lines correspond to the fits of the kinetic traces with Equation ([1](#M1){ref-type="disp-formula"}) and the *k*~obs~ values given in panel **B**. (B) Dependence of *k*~obs1~ and *k*~obs2~ (inset) values on the concentration of AZTTP. The red lines correspond to the best fits of the kinetic traces to Equation ([2](#M2){ref-type="disp-formula"}) and the IC~50~ values given in text. (**C**) Representative set of kinetic traces of 100 nM E.DNA in the absence (gray) or in the presence of increasing concentrations of Nevirapine (green---20 nM, magenta---50 nM, blue---70 nM, red---100 nM, cyan---200 nM) recorded in cuvettes. The black lines correspond to the fits of the kinetic traces with Equation ([1](#M1){ref-type="disp-formula"}) and the *k*~obs~ values given in panel **D**. (D) Dependence of *k*~obs1~ and *k*~obs2~ (inset) values on the concentration of Nevirapine. The *k*~obs~ values were obtained from the fit of the kinetic traces in panel C to Equation ([1](#M1){ref-type="disp-formula"}). The red lines correspond to best fit of the data to Equation ([2](#M2){ref-type="disp-formula"}) and the IC~50~ values given in the text. Excitation and emission wavelengths were 540 and 580 nm, respectively.](gkv1532fig3){#F3}

Similar dose-dependent decrease in the values of *k*~obs1~ and *k*~obs2~ was observed upon addition of Nevirapine to E.DNA complex (Figure [3C](#F3){ref-type="fig"} and [D](#F3){ref-type="fig"}). *IC*~50~ values for Nevirapine calculated from *k*~obs1~ (Figure [3D](#F3){ref-type="fig"}) and *k*~obs2~ (Figure [3D](#F3){ref-type="fig"}, inset) were found to be 71 (±8) nM and 74 (±9) nM, respectively. Once again, these *IC*~50~ values were similar to previously reported *IC*~50~ values ([@B48],[@B60]). Thus, the assay appears highly relevant for quantitatively determining the potency of RT inhibitors.

Finally, in order to evaluate the quality of the assay for high-throughput screening (HTS) applications, we calculated a Z-factor for the *k*~obs1~ and *k*~obs~*~2~* values at each inhibitor concentration, using Equation ([3](#M3){ref-type="disp-formula"}): $$\documentclass[12pt]{minimal}
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}{}\begin{equation*} Z = 1 - \frac{{3*SD_{{\rm Sample}} + 3*SD_{{\rm control}} }}{{{\rm mean}_{{\rm Sample}} - {\rm mean}_{{\rm control}} }} \end{equation*}\end{document}$$ where mean and SD, corresponds to the mean and standard deviation of the *k*~obs~ values for three different sets of experiments. The control values corresponded to the *k*~obs~ values in the absence of inhibitor. The Z factor is a quantitative parameter of the dynamic range and data variation associated with the measured signal in the assay ([@B61]). Except for the low inhibitor concentrations, we observed Z-factors in the range of 0.5 to 0.89 for both AZTTP and Nevirapine (Figure [4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}), showing the excellent sensitivity and robustness of the assay ([@B61]).

![Z-factor of the assay. Z-factor values for *k*~obs1~ (open squares) and *k*~obs2~ (closed disks). These values were calculated for (**A**) AZTTP and (**B**) Nevirapine according to Equation ([3](#M3){ref-type="disp-formula"}).](gkv1532fig4){#F4}

Use of the assay to monitor the concerted activity of NCp7 and RT {#SEC3-3}
-----------------------------------------------------------------

Emergence of resistance to highly active antiviral therapy and notably RT inhibitors remains a critical problem in HIV-1 patient management. Development of new antiviral agents targeting multiple HIV-1 proteins could limit cross-resistance observed with the currently used drugs ([@B62]--[@B68]). A particularly attractive complementary target to RT could be the highly conserved NCp7 protein ([@B13]--[@B15]), that is thought to promote reverse transcription in the RTC. In this context, the disclosure of hits that would target simultaneously RT and NCp7 could be of utmost interest.

We investigated whether the joint activities of RT and NCp7 could be monitored using our FRET based assay. In the presence of 1 μM of NCp7, we observed a 3-fold increase in both *k*~obs1~ and *k*~obs2~ values, as well as a small increase in the final fluorescence plateau (Figure [5A](#F5){ref-type="fig"}, orange trace and Figure [5B](#F5){ref-type="fig"}), indicating that our assay can sensitively monitor the promotion by NCp7 of the RT polymerization activity. Noticeably, no significant change in the emission of p/t labeled only by the FRET donor was observed in the presence of NCp7 (Supplementary Figure S3), suggesting that no noticeable NCp7-induced aggregation of p/t occurred in these conditions. This is likely the consequence of the high Mg^2+^ concentration in the polymerization buffer that was shown to strongly reduce the nucleic acid aggregation properties of NCp7 ([@B23]). To further validate our assay, and notably its ability to screen for NCp7 inhibitors, we monitored the effect of WDO-217 on RT polymerization in the presence of NCp7. WDO-217 is a phenyl-thiadiazolylidene-amine derivative that binds to NCp7 and efficiently ejects zinc from its two zinc fingers, even when NCp7 is bound to nucleic acids, inhibiting the nucleic acid chaperone activity of NCp7 ([@B69]). The addition of WDO-217 led to a full inhibition of the NCp7 effect on RT polymerization, providing the same kinetic parameters and fluorescence plateau as compared to RT alone (Figure [5A](#F5){ref-type="fig"}, compare magenta and green traces, and Figure [5B](#F5){ref-type="fig"}). In contrast, WDO-217 showed no effect on RT (Figure [5A](#F5){ref-type="fig"}, compare green and dark blue traces). The inhibition of NCp7 activity likely results from the previously demonstrated change in its binding mode to nucleic acids, as a result of zinc ejection ([@B69]). The binding mode of the zinc-depleted NCp7 is likely dominated by electrostatic interactions with the phosphate groups of the oligonucleotide backbone and is thought to prevent the nucleic acid chaperone properties of NCp7 as well as its productive interaction with RT. This has been verified by replacing NCp7 with NCp7(SSHS), a mutant that is unable to bind zinc ([@B70]) but still binds nucleic acids with high affinity ([@B71]). This mutant provided similar polymerization profile (Figure [5A](#F5){ref-type="fig"}, black trace) and kinetic parameters (Figure [5B](#F5){ref-type="fig"}) as compared to RT alone, mimicking the condition where WDO-217 is added to NCp7. Unfortunately, the additional control using an inhibitor of both proteins could not be performed as no molecule to our knowledge has been reported to be active both on RT polymerization and NCp7.

![RT polymerization in the presence of NCp7 and an NCp7 inhibitor. (**A**) Kinetic traces of 100 nM E.DNA in the absence (green) and in the presence of 1 μM NCp7 (orange) or 10 μM WDO (blue) or 1 μM NCp7(SSHS) (black). The magenta trace was recorded for 100 nM E.DNA in the presence of both 1 μM NCp7 and 10 μM WDO. All traces were fitted to Equation ([1](#M1){ref-type="disp-formula"}) and the rate constant values provided in panel **B**. (B) Histogram showing the *k*~obs1~ (black bars) and *k*~obs2~ (red bars) values extracted from the fits of the kinetic curves of panel A to Equation ([1](#M1){ref-type="disp-formula"}). Excitation and emission wavelengths were 540 and 580 nm, respectively.](gkv1532fig5){#F5}

Taken together, our data indicate that our direct and continuous assay can monitor the concerted activity of NCp7 and RT, and has the potential to identify molecules that inhibit one of these proteins or both at the same time.

CONCLUSION {#SEC4}
==========

Here, we describe an efficient, robust and reproducible real-time assay to screen for RT inhibitors, by monitoring RT polymerization through changes in the FRET signal of a doubly-labeled p/t duplex. In contrast to most existing assays ([@B28]--[@B42]), this assay is a continuous one-step and one-pot method that does not require cumbersome sample handling. Moreover, it presents the advantage to use commercially available fluorescently labeled oligonucleotides and non-modified RT. This is in contrast to previous assays that require fluorescent or radiolabeled nucleosides ([@B28]--[@B42]) or the preparation and purification of fluorescently-labeled RT ([@B43]--[@B47]). Using AZT and Nevirapine as representative examples of NRTI and NNRTI, respectively, it was found that both compounds dramatically decreased the kinetic rate constants and the fluorescence plateau of the FRET-based progress curves. From the dependence of the kinetic rate constants on the inhibitor concentration, reliable *IC*~50~ values were obtained for both inhibitors. Moreover, the assay shows high Z-factor values, showing its high sensitivity and suitability for HTS. In addition, the assay proved useful to monitor the promotion by NCp7 of RT polymerization. This promotion was fully reverted by the addition of an NCp7 inhibitor, indicating that this assay can also disclose NCp7 inhibitors. Therefore, the assay appears highly potent, being able to screen for RT and NCp7 inhibitors, as well as for compounds targeting the two proteins. The latter would be of high interest, as RT inhibitors are prone to resistance while due to its high conservation, NCp7 inhibitors are thought to be much less prone to resistance ([@B15],[@B16]). Finally, due to its simplicity and ease to use, our one-pot and one-step FRET-based assay will certainly be useful for monitoring the activity of other eukaryotic and prokaryotic polymerases, in order to substitute previous assays using more sophisticated fluorescence-based techniques ([@B72]--[@B77]) or radiolabeled substrates ([@B78]--[@B80]). Of course, the assay is expected also to present some limitations, the main one being the interference by the auto-fluorescent compounds in the libraries used for screening. Nevertheless, as we are using TMR and CY5 that absorb above 500 nm, the number of such interfering compounds should be limited. Another limitation will be provided by DNA intercalators that will alter the RT polymerization activity, and thus appear as false positives.
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